World Journal of Gastrointestinal Oncology最新文献

{"title":"Deep learning radiomics: Redefining precision oncology through noninvasive insights into the tumor immune microenvironment.","authors":"Mesut Tez","doi":"10.4251/wjgo.v17.i7.108175","DOIUrl":"10.4251/wjgo.v17.i7.108175","url":null,"abstract":"<p><p>Computed tomography-based deep learning radiomics provides a novel, noninvasive approach to predicting the tumor immune microenvironment in colorectal cancer, revolutionizing precision oncology. The retrospective study by Zhou <i>et al</i> analyzed preoperative computed tomography scans from 315 patients using convolutional neural networks, achieving robust predictive performance (area under the curve: 0.851-0.892) for critical tumor immune microenvironment features, such as tumor-stroma ratio and lymphocyte infiltration, without requiring invasive biopsies. This editorial explores how this technique advances personalized immunotherapy, chemotherapy, and targeted therapies; challenges conventional oncology practices; and paves the way for a future of precision medicine. By integrating advanced imaging with immune profiling, deep learning radiomics redefines colorectal cancer management, highlighting the need to re-evaluate the interplay of technology, biology, and ethics in gastrointestinal oncology.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"108175"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of endoscopic ultrasound in staging of pancreatic cancer.","authors":"Xin Yang, Nan Ge","doi":"10.4251/wjgo.v17.i7.107670","DOIUrl":"10.4251/wjgo.v17.i7.107670","url":null,"abstract":"<p><p>Pancreatic cancer is recognized as one of the leading causes of cancer mortality, representing the second most common source of cancer-related deaths within the gastrointestinal domain. Surgical resection is currently the only definitive treatment; however, the subtle emergence of symptoms often leads to a diagnosis at an advanced stage, with merely 10%-15% of patients being eligible for surgical intervention. The primary obstacle to achieving a potential radical resection is the presence of distant metastatic disease or invasion of adjacent major vascular structures. This review aims to highlight the critical role of endoscopic ultrasound in the diagnosis and staging of pancreatic tumors. We systematically searched PubMed, MEDLINE and Web of Science by using 'pancreatic cancer' and 'endoscopic ultrasonography' as keywords. Relevant studies were reviewed and analyzed. Endoscopic ultrasonography (EUS) is efficient in the diagnosis and staging of pancreatic cancer, past studies reported the accuracy of EUS is 63% to 94% for T-staging and 44% to 82% for N-staging but there are still limitations that need to be comprehensively applied with other diagnostic methods to evaluation of distant metastasis for surgical resectability. Our review aims to reveal the value for the staging of pancreatic cancer.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"107670"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flap endonuclease-1 promotes pancreatic cancer progression <i>via</i> AKT/mTOR signaling pathway.","authors":"Yu Xia, Na Guo, Cheng-Lou Zhu, Jie-Yun Gao, Ming-Xu Da","doi":"10.4251/wjgo.v17.i7.104402","DOIUrl":"10.4251/wjgo.v17.i7.104402","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer (PC) remains one of the most lethal malignancies. While flap endonuclease-1 (FEN1) has been implicated in various cancers, its role in PC remains unclear.</p><p><strong>Aim: </strong>To investigate the biological functions and mechanisms of FEN1 in PC progression.</p><p><strong>Methods: </strong>FEN1 expression and its prognostic significance were analyzed using Gene Expression Omnibus, The Cancer Genome Atlas, and Genotype-Tissue Expression databases. FEN1 was knocked down or overexpressed in PC cell lines using lentiviral vectors. Cell proliferation, migration, and invasion were assessed <i>in vitro</i>, while tumorigenicity was evaluated in nude mouse xenografts. Molecular mechanisms were explored through RNA-sequencing and validated by western blot analysis.</p><p><strong>Results: </strong>FEN1 was significantly upregulated in PC tissues and correlated with poor prognosis. FEN1 promoted PC cell proliferation, migration, and invasion <i>in vitro</i>, as well as xenograft tumor growth <i>in vivo</i>. Mechanistically, FEN1 regulated epithelial-mesenchymal transition through the AKT/mTOR signaling pathway.</p><p><strong>Conclusion: </strong>FEN1 functions as an oncogenic driver in PC progression <i>via</i> the AKT/mTOR signaling pathway, suggesting its potential as a therapeutic target.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"104402"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insurance coverage and patient outcomes: Understanding changes in esophageal cancer treatment.","authors":"Arvind Mukundan, Yaswanth Nagisetti, Riya Karmakar, Hsiang Chen Wang","doi":"10.4251/wjgo.v17.i7.107154","DOIUrl":"10.4251/wjgo.v17.i7.107154","url":null,"abstract":"<p><p>The article by Wu <i>et al</i> highlights the growing incidence of esophageal tumor patients, particularly in China, where the high frequency and death rate are significant problems. The article also examined the impact of health insurance on treatment availability and patient outcomes, demonstrating that the type of insurance can affect the financial burden on patients. This study investigates the effects of different types of health care coverage, namely Urban Employee Basic Medical Insurance <i>vs</i> Urban-Rural Resident Basic Medical Insurance, and the personal spending ratio on treatment decisions and survival outcomes. The database used is derived from esophageal tumor patient continuation from Chongqing University Hospital in China. A total of 2543 patients were included in the study, allowing for the formation of research cohorts. Patient information included demographic characteristics. The study followed various processes to maintain consistency, including data sources, inclusion and exclusion criteria, follow-up duration, health insurance, and statistical analysis. The average age at diagnosis ranged from 57-74 years, and predominantly included men, married people, and those of Han ethnic background, comprising 2088 and 2519 individuals, respectively. Upon controlling for age, sex, relationship status, country of origin, pathological evaluation, tumor stage, and biochemical indicators, individuals who had Urban Employee Basic Medical Insurance exhibited a higher propensity to opt for radiotherapy, chemotherapy, immunotherapy, and targeted therapy compared to those covered by the Urban-Rural Resident Basic Medical Insurance. During the follow-up phase of the study, a total of 1438 deaths were documented, with 1106 ascribed to esophageal cancer. Additionally, individuals with Urban-Rural Resident Basic Medical Insurance had a significantly elevated risk of esophageal cancer, particularly mortality, compared to those without Urban-Rural Resident Basic Medical Insurance.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"107154"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and challenges in drug repurposing in precision therapeutics of colorectal cancer.","authors":"Xin-Ning Yu, Hua-Tao Wu, Bing-Xuan Wu, Shu-Feng Zhi, Yang-Zheng Lan, Wen-Jia Chen, Jing Liu","doi":"10.4251/wjgo.v17.i7.107681","DOIUrl":"10.4251/wjgo.v17.i7.107681","url":null,"abstract":"<p><p>Colorectal cancer (CRC) ranks as the third most common cancer globally and the second leading cause of cancer-related deaths, representing a significant health burden. Despite advancements in traditional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, these approaches still face challenges, including high costs, limited efficacy, and drug resistance. Drug repurposing has emerged as a promising strategy for CRC treatment, offering advantages with reduced development timelines, lower costs, and improved drug accessibility. This review explores drug repurposing strategies for CRC, supported by multidisciplinary technologies, and discusses the current challenges in the field.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"107681"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between blood metabolite levels and gastrointestinal cancer risk: A preliminary untargeted metabolomics study.","authors":"Tian-Hao Guo, Wen-Jian Zhu, Yi-Fan Hui, Shuo-Qi Zhao, Ting-Ting Zhou, Xue-Meng Wang, Qin-Chang Zhang, Wei Wang, Liu Li, Wei-Xing Shen, Xiao-Yu Wu, Hai-Bo Cheng","doi":"10.4251/wjgo.v17.i7.104860","DOIUrl":"10.4251/wjgo.v17.i7.104860","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal cancers are among the most commonly diagnosed cancers globally. Traditional Chinese medicine (TCM) offers distinct advantages in preventing and treating these cancers.</p><p><strong>Aim: </strong>To investigate the metabolic basis of a common TCM syndrome in gastrointestinal cancers, exploring underlying metabolic mechanisms and identifying potential biomarkers.</p><p><strong>Methods: </strong>Thirty healthy controls (normal group), 30 patients with gastric cancer (GC), and 30 patients with colorectal cancer (CRC) were enrolled in 2023. Plasma metabolic profiles were detected using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry, and pathway enrichment analysis was conducted using the Kyoto Encyclopedia of Genes and Genomes.</p><p><strong>Results: </strong>Metabolic profiling revealed distinct alterations in gastrointestinal cancers. CRC samples exhibited 455 differentially expressed metabolites (234 upregulated and 221 downregulated). Similarly, GC samples exhibited 459 differentially expressed metabolites (251 upregulated and 208 downregulated). Additionally, 352 shared metabolites were identified among gastrointestinal cancers. Enrichment analysis highlighted the involvement of these shared metabolites in 10 metabolic pathways.</p><p><strong>Conclusion: </strong>To some extent, this study revealed the metabolomic characteristics of spleen deficiency and blood stasis toxin (PXYD) syndrome in gastrointestinal cancers. It provides the rationale for the \"same treatment for different diseases\" approach in PXYD syndrome of gastrointestinal cancers, and for identifying potential metabolomics-based biomarkers.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"104860"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yttrium-90 microsphere therapy for hepatocellular carcinoma: Clinical efficacy, mechanistic insights, and comparative therapeutic perspectives.","authors":"Yu-Hang Zhu, Ming-Wei Wang, Yan Jiao, Ya-Hui Liu, Shan-Shan Dong","doi":"10.4251/wjgo.v17.i7.109379","DOIUrl":"10.4251/wjgo.v17.i7.109379","url":null,"abstract":"<p><p>Yttrium-90 (Y-90) microsphere therapy, known as radioembolization, has emerged as a pivotal treatment modality for hepatocellular carcinoma (HCC), delivering targeted radiation with minimal collateral damage to healthy liver tissues. This review meticulously synthesizes current evidence regarding the clinical efficacy, underlying therapeutic mechanisms, patient selection criteria, and comparative advantages of Y-90 therapy. Clinical studies consistently demonstrate significant improvements in overall survival and progression-free survival, coupled with robust tumor response rates and manageable adverse events. The therapy's efficacy is substantially enhanced by advanced dosimetric techniques, enabling precise radiation delivery tailored to individual tumor profiles. Comparative analyses reveal that Y-90 therapy provides superior local tumor control and a preferable safety profile compared to conventional treatments such as transarterial chemoembolization and external beam radiation therapy. Additionally, its clinical outcomes are comparable to those achieved with contemporary systemic therapies. Ongoing research into combination treatments incorporating Y-90 with systemic therapies, including targeted agents and immune checkpoint inhibitors, suggests promising advancements in comprehensive HCC management. Future directions highlight the necessity for continued refinement of dosimetry and patient stratification approaches, aiming to further optimize therapeutic outcomes.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"109379"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of prognostic factors and their differences in intrahepatic, hilar, and distal cholangiocarcinoma: A systematic review and meta-analysis.","authors":"Muhammad Masroor Hussain, Ju-Mei Wang, Ao-Qiang Zhai, Fu-Yu Li, Hai-Jie Hu","doi":"10.4251/wjgo.v17.i7.107995","DOIUrl":"10.4251/wjgo.v17.i7.107995","url":null,"abstract":"<p><strong>Background: </strong>Cholangiocarcinoma (CCA) comprises heterogeneous malignancies arising at different anatomical locations: Intrahepatic cholangiocarcinoma (IHCC), perihilar cholangiocarcinoma (PHCC), and distal cholangiocarcinoma (DCC). These subtypes exhibit distinct clinical behaviors, treatment approaches, and outcomes. Despite advances in surgical and adjuvant therapies, the prognostic implications of tumor location remain unclear and inconsistently reported. Understanding these variations is essential for personalized management and staging refinement. We hypothesized that the anatomical subtype of CCA significantly influences prognostic outcomes and pathological features.</p><p><strong>Aim: </strong>To compare prognostic outcomes and clinicopathological characteristics among IHCC, PHCC, and DCC based on current evidence.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, EMBASE, and the Cochrane Library were searched, yielding 11 eligible retrospective comparative studies involving 14484 patients (IHCC: 6260; PHCC: 6895; DCC: 1329). Outcomes assessed included overall survival (OS), lymph node metastasis, neural invasion, and vascular invasion. Statistical analyses were performed using RevMan 5.3 and Stata 13.0.</p><p><strong>Results: </strong>DCC demonstrated the most favorable prognosis among all subtypes. Despite the highest lymph node metastasis rate (DCC: 56.9%), it was associated with better OS than PHCC and IHCC. Vascular invasion was more prevalent in IHCC (OR = 1.66, 95%CI: 1.22-2.28, <i>P</i> = 0.001). OS comparisons showed no significant difference between PHCC and IHCC (HR = 1.02, <i>P</i> = 0.88), while DCC showed consistent trends toward better survival against both.</p><p><strong>Conclusion: </strong>Anatomical subtype is a significant prognostic factor in CCA. DCC patients experience superior outcomes despite aggressive lymphatic spread, suggesting better resectability and surgical outcomes. These insights underscore the need for subtype-specific management strategies and future prospective validation.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"107995"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stemness signatures reflect prognostic disturbances in gastric cancer.","authors":"Wen-Feng Pu, Xiao Yang, Xiao-Qing Wang, Xiao-Guang Guo, Mi-Yuan Yang","doi":"10.4251/wjgo.v17.i7.107211","DOIUrl":"10.4251/wjgo.v17.i7.107211","url":null,"abstract":"<p><strong>Background: </strong>Tumors characterized by high cellular stemness often have unfavorable clinical outcomes, primarily due to their heightened potential for metastasis and resistance to chemotherapy. Among the model genes, the clinical relevance and prognostic significance of Niemann-Pick type C2 (NPC2) in gastric cancer (GC) remained largely unexplored.</p><p><strong>Aim: </strong>To identify stemness-associated genes in GC.</p><p><strong>Methods: </strong>In this study, epithelial cells were categorized as either tumor or normal epithelial cells using the infer copy number variation method. Stemness scores were calculated for both cell types. The hierarchical Weighted Gene Co-expression Network Analysis identified two gene modules with the strongest association with stemness. Prognostically significant stemness-related genes were pinpointed using univariate Cox regression based on The Cancer Genome Atlas dataset. A predictive model related to stemness was constructed using Least Absolute Shrinkage and Selection Operator regression followed by multivariate Cox analysis.</p><p><strong>Results: </strong>Functional roles of NPC2 were validated using single-cell and bulk RNA sequencing data. Further experimental validation revealed that elevated NPC2 expression promoted tumor cell stemness, invasiveness, migratory ability, and resistance to standard chemotherapeutic agents. Importantly, high NPC2 expression correlated with poorer overall survival in GC patients.</p><p><strong>Conclusion: </strong>In summary, the proposed model offers prognostic insights that outperform traditional clinical staging and may inform more tailored therapeutic approaches for gastric cancer management.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"107211"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing T-cell response with monoclonal antibodies and chemotherapy in advanced gastric cancer.","authors":"Ana Carolina Pires, Pedro Luiz Serrano Uson Junior","doi":"10.4251/wjgo.v17.i7.104806","DOIUrl":"10.4251/wjgo.v17.i7.104806","url":null,"abstract":"<p><p>This article provides a critical analysis of a prospective single arm study by Zheng <i>et al</i>, which assessed the impact of oxaliplatin and trastuzumab, administered every 3 weeks, for a total of six cycles in 60 patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. The study specifically explored how this treatment regimen influenced serum tumor markers and T lymphocyte subsets. After six cycles of treatment, the levels of the tumor markers carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 72-4 in the blood significantly dropped compared to their initial values (<i>P</i> < 0.001). There was a notable increase in the percentages of CD3+ and CD4+ T cells (<i>P</i> < 0.05), while the percentage of CD8+ T cells decreased (<i>P</i> < 0.05). As a result, the CD4+/CD8+ ratio also rose significantly after treatment (<i>P</i> < 0.05). Patients who had a reduction of 50% or more in their tumor markers and an increase of 1.5 times or more in the CD4+/CD8+ ratio showed better clinical improvements (<i>P</i> < 0.05). In this editorial, we will discuss these findings and how they apply to the current treatment field for advanced HER2 positive gastric cancer.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 7","pages":"104806"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}